Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $7.0 million.

  • Akebia Therapeutics' Prepaid Assets fell 4771.54% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 4771.54%. This contributed to the annual value of $11.4 million for FY2024, which is 4393.12% down from last year.
  • Per Akebia Therapeutics' latest filing, its Prepaid Assets stood at $7.0 million for Q3 2025, which was down 4771.54% from $7.8 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Prepaid Assets peaked at $42.1 million during Q2 2022, and registered a low of $7.0 million during Q3 2025.
  • Moreover, its 5-year median value for Prepaid Assets was $20.2 million (2023), whereas its average is $21.2 million.
  • In the last 5 years, Akebia Therapeutics' Prepaid Assets soared by 33711.41% in 2021 and then plummeted by 5869.42% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Prepaid Assets stood at $33.1 million in 2021, then fell by 0.83% to $32.9 million in 2022, then tumbled by 38.4% to $20.2 million in 2023, then crashed by 43.93% to $11.4 million in 2024, then tumbled by 38.1% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $7.8 million for Q2 2025, and $9.1 million during Q1 2025.